Who is sponsoring NCT04384965?

NCT04384965 is sponsored by Centre for Addiction and Mental Health.

What drugs are being tested in NCT04384965?

Interventions in NCT04384965: MagPro X100 Stimulator, B70 Fluid-Cooled Coil.

What condition does NCT04384965 study?

NCT04384965 studies Major Depressive Disorder.

Is NCT04384965 still recruiting?

NCT04384965 is currently completed. Last updated 20 February 2024.

Last reviewed 2024-02-20 · How we verify

NCT04384965

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic

Completed NA Last updated 20 February 2024

What this trial tests

NA trial testing MagPro X100 Stimulator, B70 Fluid-Cooled Coil in Major Depressive Disorder in 176 participants. Completed in 1 November 2022.

Timeline

12 May 2020

Primary endpoint
18 May 2022

1 November 2022

Quick facts

Lead sponsor	Centre for Addiction and Mental Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	176
Start date	12 May 2020
Primary completion	18 May 2022
Estimated completion	1 November 2022
Sites	1 location across Canada

Drugs / interventions tested

MagPro X100 Stimulator, B70 Fluid-Cooled Coil

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Centre for Addiction and Mental Health — full company profile →

Who can join

18 and older, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose aiTBS protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with unipolar depression previously responsive to ECT and patients needing urgent treatment due to symptom severity during the COVID-19 pandemic.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Accelerated Intermittent Theta Burst Stimulation in Late-Life Depression: A Possible Option for Older Depressed Adults in Need of ECT During the COVID-19 Pandemic.
Konstantinou GN, Downar J, Daskalakis ZJ, Blumberger DM. · · 2020 · cited 14× · PMID 32753340 · DOI 10.1016/j.jagp.2020.07.007
Extended course accelerated intermittent theta burst stimulation as a substitute for depressed patients needing electroconvulsive therapy.
Goodman MS, Trevizol AP, Konstantinou GN, Boivin-Lafleur D, et al · · 2025 · cited 4× · PMID 39443721 · DOI 10.1038/s41386-024-02007-w
Accelerated intermittent theta burst as a substitute for patients needing electroconvulsive therapy during the COVID-19 pandemic: study protocol for an open-label clinical trial
Blumberger DM, Daskalakis ZJ, Vila-Rodriguez F, Boivin-Lafleur D, et al · · 2020 · DOI 10.1101/2020.12.15.20248260

Verify or expand the search:

Other trials of MagPro X100 Stimulator, B70 Fluid-Cooled Coil

Trials testing the same drug.

NCT04427137 — Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic · NA · completed

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Centre for Addiction and Mental Health trials

Trials by the same sponsor.

NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04384965 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
Last refreshed: 20 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04384965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing